← Browse by Condition
Medical Condition

camrelizumab

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for camrelizumab sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — camrelizumab Clinical Trials

How many clinical trials are currently recruiting for camrelizumab?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for camrelizumab, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for camrelizumab?
camrelizumab research spans Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a camrelizumab clinical trial?
Eligibility criteria for camrelizumab trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Top Sponsors
Zhenzhen Liu 1 trial
Peking University Cancer Hospital & Institute 1 trial
Sun Yat-sen University 1 trial

Recruiting Clinical Trials

NCT05475678 Phase 2
Recruiting
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Enrollment
369 pts
Location
China
Sponsor
Zhenzhen Liu
View Trial →
NCT05512481 Phase 2
Recruiting
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Enrollment
60 pts
Location
China
Sponsor
Peking University Cancer Hospi...
View Trial →
NCT06061276
Recruiting
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
Enrollment
40 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →

Related Conditions

breast cancer (1) triple negative breast cancer (1) melanoma (1) acral melanoma (1) temozolomide (1) apatinib (1) neoadjuvant (1) pathological response (1) liver diseases (1) hepatocellular carcinoma (1) immunotherapy (1) lenvatinib (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology